Select Page

South Delhi Pharma, New Delhi, India

TIBSOVO ® (ivosidenib tablets), for oral use.

Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email query@southdelhipharma.com to discuss.

TIBSOVO is a prescription medicine. TIBSOVO is used to treat acute myeloid leukemia (AML).
INDICATIONS AND USAGE
TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of adult patients with relapsed or ref
DOSAGE FORMS & STRENGTHS
Tablets: 250 mg
Manufactured By: Agios Pharmaceuticals
Prescribing Information URL: Click Here

South Delhi Pharma can facilitate the supply of “TIBSOVO ® (ivosidenib tablets)” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.

Category:

Get In Touch

Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.

The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.

Contact Number:
M:+91-9891296838 / P:+91-11- 26532129

Email ID:
info@southdelhipharma.com

15 + 14 =

Ivosidenib, sold under the brand name Tibsovo, is a medication for the treatment of acute myeloid leukemia (AML). It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials.[when?] The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and cholangiocarcinoma.

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.

In 2018, ivosidenib was approved in the United States for relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation and is presently[when?] in a phase III clinical trial for cholangiocarcinoma with an IDH1 mutation.

In 2019, ivosidenib was approved in the United States for newly diagnosed acute myeloid leukemia (AML) with a susceptible IDH1 mutation, as detected by an FDA-approved test, in patients who are at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.

Reviews

There are no reviews yet.

Be the first to review “TIBSOVO ® (ivosidenib tablets), for oral use.”

Your email address will not be published.